Shares of Macrocure Ltd (NASDAQ:MCUR) are on fire once again this morning. The stock has seen a tremendous amount of volume in early morning trading, regaining a good portion of the losses that they had suffed at the end of October.
Shareholders seem to have perhaps regained confidence in the company after a decent earnings report on November 17th. It will be interesting to see if the stock can regain its mojo it had in early-to-mid October.The stock is up 37.22% or $0.72 after the news, hitting $2.66 per share. About 1.38M shares traded hands or 0.73% up from the average. MCUR has declined 80.60% since April 24, 2015 and is downtrending. It has underperformed by 79.24% the S&P500.
Out of 5 analysts covering Macrocure (NASDAQ:MCUR), 0 rate it “Buy”, 0 “Sell”, while 5 “Hold”. This means 0 are positive. $20 is the highest target while $1 is the lowest. The $7.50 average target is 181.95% above today’s ($2.66) stock price. Macrocure was the topic in 9 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Zacks upgraded the stock on September 7 to “Hold” rating. Oppenheimer maintained the shares of MCUR in a report on August 20 with “Perform” rating.
MacroCure Ltd. is a biotechnology company. The company has a market cap of $44.48 million. The Firm is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs in the treatment of chronic and other hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers (VLUs). It currently has negative earnings. The Company’s product candidate, CureXcell, is an advanced wound care (AWC) therapy to treat such wounds by injecting living human white blood cells that have been activated to facilitate the healing process.